New biological targets for CKD- MBD: From the KDOQI to the
|
|
- Chad Holmes
- 6 years ago
- Views:
Transcription
1 New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. guillaume-jean-crat@wanadoo.fr
2 Introduction From 2003 to 2009 the recommendations were the Kidney Disease: Outcomes Quality Improvement (KDOQI) for mineral metabolism abnormalities. Biological targets and therapeutic strategies have been defined precisely and were used by nephrologists and in all clinical trials and observatories. In 2009, the new recommendations were released with the Kidney Disease: Improving Global Outcomes (KDIGO).
3
4 Grading differences KDIGO
5 KDOQI Grading evidence Highest quality Randomized controlled trials Matched controlled trials Prospective nonrandomized/nonmatched controlled trials Retrospective nonrandomized/nonmatched controlled trials KDIGO
6 NEW TARGET FOR PHOSPHATAEMIA
7
8 New KDIGO target In patients with CKD stages 3 5, we suggest maintaining serum phosphorus in the normal range (2C). In patients with CKD stage 5D, we suggest lowering elevated phosphorus levels toward the normal range (2C). Normal values for phosphaetamia 0,81 1,45 mmol/l (2,5 4,5 mg/dl) KDIGO
9 EVIDENCE? Risque Relatif de Mortalité (RR) KDOQI % Phosphorémie (mmol/l) +39 % +18 % Phosphorémie mmol/l Adapted from Block GA, et al. Am J Kidney Dis. 1998;31:
10 Observational data in the USA 2,5 mmol/l KDIGO GA Block et al. J Am Soc Nephrol 2004,15:2208.
11 Phosphataemia and survival in the DOPPS study <0,6 mmol > 2,2 mmol > 3 mmol KDIGO Tentori et al; AJKD 2008: 52: 519-
12 Phosphocalcic Metabolism and 1 year Survival (French cohort Photograph) Age (yr) < Gender F/M CV history < Diabetes BMI (kg/m2) < Low serum P High serum P Low serum PTH High serum PTH Low serum Ca High serum Ca Hemoglobin (g/l) < Albumin (g/l) < N = 4,937. Models were adjusted for age, sex, BMI, diabetes, history of CV disease, serum albumin, hemoglobin, and baseline serum levels of total calcium, phosphorus and PTH. Patients with recent parathyroidectomy (less than 6 months) were excluded from the analysis. D Fouque et al, WCN, Milan, 2009
13 Causes of hyperphosphataemia: Excess protein intake (> 1,2 g/kg/j) Excess phosphate intake (> 1000 mg/j) Inadequate dialysis removal : time, frequency, efficiency Inadequate phosphate binding: timing, dosage, side effects, compliance Excess active vitamin D (+ adynamic bone disease) Secondary hyperparathyroidism GA. Block et al, Am J Kidney Dis 2000,35:1226.
14 Phosphate intake is linked with protein intake Protein intake (g/kg/jour) Phosphate intake (mg) > ± ± ± ± 142 < ± 105 Rufino M, et al. Nephrol Dial Transplant. 1998;13:65 67.
15 The amount of phosphorus removal depends on clearance, frequency and treatment time. Gotch et al;blood Purif 2003, 21:51-57.
16 Achieving the old target KDOQI 60 1,13 1,78 mmol/l 50 Relative frequency (%) % 54% 29% ARNOS Rhône-Alpes, D. Fouque et al, 2005 Ph KDOQI
17 70% of dialysis patients in the USA were hyperphosphataemic in the 90s 25% Patients Above Normal Percentage of Patients 20% 15% 10% 5% 0% Serum Phosphorus (mmol/l) CMAS (1990) mean = 2.00 DMMS (1993) mean = Block GA, et al. Am J Kidney Dis. 1998;31:
18 Achieving the new target KDIGO mmol/ l 56% mmol/l Relative frequency (%) % 10 12% Ph KDIGO 2009
19 Questions What is the better day for biological sampling? 1st day of the week, mid-week? Morning, evening, nighttime? Circadian cycle and dietary intake? What is «lowering toward the normal range»? some pitfalls: Lowering phosphataemia from 3.5 to 2.5 mmol/l may seems enough Being happy with malnourish patient with phosphataemia at 1 mmol/l
20 Normal phosphataemia? Phosphataemia mmol Case n 1 Case n 2 Case n 3 1,1 1,1 1,1 Calcaemia mmol/l Albumin g/l PTH pg/ml B-ALP µg/l npcr g/kg/j Kt/V Session time 3 x 4h 3 x 4h 3 x 8 h Caco3 mg/j Alfacalcidol µg/s BMI kg/m² Age years
21 Conclusion on phosphataemia target (Tend to) normalizing phosphataemia would help (theoretically) in decreasing CV mortality (calcification), but this is not based on any data. Normalizing phosphataemia needs to: Decrease protein intake Increase phosphate binder dosage Increase dialysis (time/frequency) Increase medical cost, limited by compliance Post-dialysis hypophosphataemia (< 0.5 mmol/l) may be harmful (neuromuscular, osteomalacia)
22 NEW PTH TARGET
23
24 High turnover for PTH pg/ml
25 Low turnover for PTH < 60 pg/ml
26 PTH and «The optimal target level of PTHi in CKD is not know due to limitation of data available and the emerging consensus that those target levels may be lower than currently thought» PTHi diagnose adynamic bone disease when < 60 pg/ml and high turnover bone disease when > pg/ml Eknoyan, AJKD 2003 KDOQI
27 KDIGO target for PTH In patients with CKD stage 5D, we suggest maintaining ipth levels in the range of approximately two to nine times the upper normal limit for the assay (2C) pg/ml (Roche Elecsys ) We suggest that marked changes in PTH levels in either direction within this range prompt an initiation or change in therapy to avoid progression to levels outside of this
28 KDIGO: relationship between PTH levels and the risk for fractures
29 KDIGO: relationship between PTH levels, Bone ALP and bone turnover
30 PTHi Bone turnover relationship in the 90s KDOQI From: Q. QI, AJKD, 1995,26,4:622.
31 Relationship between coronary calcifications and low PTH and calcium carbonate Caractéristiques cliniques Score de calcification Age 41 48, p 0,001 Adaptation de Guérin, NDT,2000 Ancienneté en dialyse (mois) Ca. élé t (CaCO3) 1,35 (3,3) 1,35 (3,3) 1,5 (3,4) 1,8 (3,75) 2,18 (5,5) Tabagisme (Paquets/Année) Fibrinogène (g/l) 4 4,2 4,25 5 5,1 CRP (mg/l) 5,2 7 6, PTH (pg/ml) HyperCa (%) Ca.P (mmol2/l2) 4,4 4,54 4,57 4,14 4,64 0,001 0,001 0,01 0,001 0,001 0,047 0,034 NS
32 Low PTH level is associated with arterial calcification GM London et al: e. JASN 2004,15:1943.
33 KDIGO: bone disease according to CKD stage and treatment
34 Same as in the 21th century KDIGO Baretto et al,kidney Int 2008: 73; 771
35 Upper limits PTH reference levels are disturbed by vitamin D deficiency Non vitamin D-deficient Souberbielle, J.-C. et al. J Clin Endocrinol Metab 2001;86: Copyright 2001 The Endocrine Society
36 What is your PTH assay? KDIGO Souberbielle JC, et al;kidney Int 2006;70:
37 PTH level of 300 pg/ml can be associated with different bone turnover Calcaemia Phosph PTH 25(OH)D B ALP mmol/l mmol/l pg/ml nmol/l µg/l Mild SHPT 2,15 1, Adynamic BD 2,5 1, Severe HPT 2,
38 Case N 1 T0 3 mths 6 mths Lowering BT PTH pg/ml treatment Calcaemia mmol/l 2,36 2,45 2,5 Phosphataemia mmol/l 1,6 1,7 1,8 ALP total UI/ l Case N 2 PTH pg/ml Calcaemia mmol/l 2,5 2,45 2,29 Phosphataemia mmol/l 1,9 1,7 1,5 ALP total UI/ l
39 PTH and mortality in DOPPS < 600 Tentori, AJKD 2008,52:519 KDIGO
40 PTH and survival in the USA Kalantar-Zadeh et al; Kidney Int :
41 Impact of the PTH target in a French population ± 293 pg/ml 25 Relative frequency (%) KDOQI 30% KDIGO 50 % ARNOS Rhône-Alpes, D. Fouque et al, 2005 PTH pg/ml
42 Conclusion KDIGO PTH target is wider mainly based on bone turnover criteria (supposed) Consequences: Larger uncertain zone less affected by the assay Needs a dynamic rendition rather than based on a single value Needs of real bone marker (B-ALP) Less adynamic bone disease (increasing the mean value) Less lowering PTH therapies (calcium, calcitriol analogues, cinacalcet) More hyperparathyroidism Which consequences on bone disease, vascular calcification, survival?
43 NEW CALCIUM TARGET
44 Evolution of recommendations 2003: Total corrected calcium must be maintained within the normal range for the laboratory (EVIDENCE) preferably toward the lower end (8.4 to 9.5 mg/dl [2.10 to 2.37 mmol/l]). (OPINION) KDIGO In CKD stage 3-5D, we suggest maintaining serum calcium in the normal range (2D, very low evidence). 2009: KDOQI
45 Factors Associated with Cardiac Calcification in Young Dialysis Patients KDOQI Coronary Calcification No Calcification Factor (N=14) (N=25) P Value Ca intake from calcium binders (mg/day) 6456 ± ± Serum P (mmol/l) 2.2 ± ± Ca P (mmol 2 /L 2 ) 5.3 ± ± Age (years) 26 ± 3 15 ± 5 <0.001 Mean duration of dialysis (years) 14 ± 5 4 ± 4 <0.001 Serum calcium was not significant. 1. Adapted from Goodman WG, et al. N Engl J Med. 2000;342:
46 Total calcaemia Severe Hypocalcaemia < 1.9 mmol/l Moderate Hypocalcaemia mmol/l Normal calcaemia mmol/l Mild Hypercalcaemia mmol/l Moderate Hypercalcaemia 3 3,3 mmol/l Severe Hypercalcaemia > 3.3 mmol/l Calcium, Lancet 1998,352:306. KDIGO
47 Calcium in the body
48 Calcium references? KDOQI : no reference of ionized Ca Ionized calcium is:«time consuming and money consuming» Better using Formulae: Corrected ca= Tot Ca (mg/dl) + 0,0704 X [34 alb g/l] Corrected ca= Tot Ca + 0,8 x [40 alb]
49 KDIGO Corrected calcium? Unfortunately, recent data have shown that it offers no superiority over total calcium alone and is less specific than ionized calcium measurements. The Work Group did not recommend that corrected calcium measurements be abandoned at present. Gauci C, J Am Soc Nephrol ; 1592
50 Relationship between PTH and i-calciumi the set-point PTH (%) Set point Severe SHPT Moderate SHPT Normal subject mg/dl mmol/l Ionized calcium Adapted, with permission, from Malberti F et al. Nephrol Dial Transplant 1999;14:
51 Baseline calcaemia = set-point Malberti, F., M. Farina, et al. (1999). "The PTH calcium curve and the set point of calcium in primary and secondary hyperparathyroidism." Nephrol Dial Transplant 14(10):
52 Survival and corrected calcaemia Survival and corrected calcaemia GA Block et al, Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004,15:2208.
53 Calcaemia and survival: DOPPS study 2,15 2,5 mmol/l Tentori, AJKD 2008,52:519 KDIGO
54 KDOQI 50 Relative frequency (%) % in the target mmol/l ,5 0,8 1,0 1,3 1,5 1,8 2,0 2,2 2,5 2,7 3,0 3,2 3,5 3,7 4,0 ARNOS Rhône-Alpes, D. Fouque et al, 2005 Alb-corrected calc mmol/l
55 KDIGO Relative frequency (%) % in the target mmol/l ,3 0,5 0,8 1,0 1,2 1,4 1,7 1,9 2,1 2,4 2,6 2,8 3,0 3,3 3,5 ARNOS Rhône-Alpes, D. Fouque et al, 2005 Calc totale mmol/l
56 Conclusion We move from a narrow target for albcorrected calcaemia (2.1 to 2.37 mmol/l) to a normal range for total calcaemia with twice more patients achieving the target. Consequences? Less low dialysate calcium? Less non-calcium based phosphate binder? Less SHPT? Less cinacalcet use? More vitamin D? Bone and vascular consequences?
57 KDOQI strategy: a real pitfall T0 T3 T6 T9 PTH pg/ml Alb-corrected calcaemia Total calcaemia mmol/l Phosphataemia mmol/l Ca dialysate mmol 1, CacO3 g/day 2g g Sevelamer mg/day Cinacalcet mg/day Un-alpha µg/week
58 With the KDIGO T0 T3 PTH pg/ml Corrected 2,5 2,45 calcaemia mmol/l Total calcaemia 2,45 2,4 Phosphataemia mmol/l 1,8 1,5 Ca dialysate 1,5 1,5 CacO3 g/day Lanthanum g/d 0 1 g Cinacalcet 0 0 Un alpha 0 0 Cholecalciferol U/mths
59 MORE RECOMMENDATIONS
60 KDOQI: native vitamin D In patients with more advanced CKD (Stage 5) and in dialysis patients, it is not established that nutritional replacement with vitamin D (ergocalciferol or cholecalciferol) will be effective since the ability to generate adequate levels of 1,25(OH)2D3 is markedly reduced or is unlikely.
61 KDIGO and native vitamin D In patients with CKD stages 3 5D, we suggest that 25(OH)D (calcidiol) levels might be measured, and repeated testing determined by baseline values and therapeutic interventions (2C). We suggest that vitamin D deficiency and insufficiency be corrected using treatment strategies recommended for the general population (2C).
62 nmol/l Melamed, M. L.,, et al. (2008). Arch Intern Med 168(15): 1629-
63 KDIGO and bone markers In patients with CKD stages 3 5D, we suggest that measurements of serum PTH or bone-specific alkaline phosphatase can be used to evaluate bone disease
64 Ca x P product In patients with CKD stages 3 5D, we suggest that individual values of serum calcium and phosphorus, evaluated together, be used to guide clinical practice rather than the mathematical construct of calciumphosphorus product (CaxP) (2D).
65 Biological target evolution Target Calcaemia Phosphataemia PTH Ca x P Normal range but 1,13 1, < 4,4 preferably toward mmol/l pg/ml mmol²/l² KDOQI the lower end (2,1 2,37 mmol/l ) Normal range (2,1 Toward the 2 9 time the No more 2,55 mmol/l) normal range upper limit of target KDIGO (0,8 1,45 mmol/l) the assay
66 Take home message The evidence level requirement has increased with the KDIGO, but the level of evidence remains poor. However, most of the recommendations make sense and constitute an improvement of the KDOQI, beyond the targets: The idea of dynamic rather than static interpretation Individualization rather than one size fits all A global approach not based on only one parameter To prevent rather than to cure
Secondary hyperparathyroidism in dialysis patients
Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationIpovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano
Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationTreatment Options for Chronic Kidney
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationWest Midlands guidelines for managing Chronic Kidney Disease related Mineral and Bone Disorders in Haemodialysis Patients
West Midlands Renal Network West Midlands guidelines for managing Chronic Kidney Disease related Mineral and Bone Disorders in Haemodialysis Patients WMRN/Regional Bone Management Guidelines /1010/Final
More informationIMPLEMENTATION OF THE CKD-MBD PRACTICE. Goce Spasovski, R. Macedonia
IMPLEMENTATION OF THE CKD-MBD GUIDELINES Introduction INTO CLINICAL to Renagel PRACTICE Goce Spasovski, R. Macedonia Antalya, Turkey, September 16 2012 Session Objectives Guidelines needs and controversy
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationOPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura
www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance
More informationTreatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia Budapest, August 29, 2011 Session Objectives Definition of the problem of CKD-MBD
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationManagement of CKD. Goce Spasovski, R. Macedonia
Management of CKD complications Introduction Bone disease to Renagel Goce Spasovski, R. Macedonia Istanbul, June 4, 2011 Session Objectives - Mineral and Bone Disorders (MBD) Bone disease a part of CKD
More informationGuidelines and new evidence on CKD - MBD treatment
Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More informationClinical Guideline Bone chemistry management in adult renal patients on dialysis
Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L
More informationThe Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD
The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD Jess Tower MS RD LD 3/18/19 Children s Mercy Hospital jdtower@cmh.edu 816 460 1067 Disclosures Nothing to disclose 1 How
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationNutrition and Renal Disease Update
Nutrition and Renal Disease Update Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France What have we learned? 1. Chronic kidney disease:
More informationCardiovascular (CV) disease is the main cause of death
www.kidney-international.org Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients OPEN Emilie Merle 1, Hubert
More informationPREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL
PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL DR. ANNE MUGERA The Problem Chronic Kidney disease is a worldwide
More informationOutline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010
Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationYing Liu, 1 Wen-Chin Lee, 2 Ben-Chung Cheng, 2 Lung-Chih Li, 2 Chih-Hsiung Lee, 2 Wen-Xiu Chang, 1 and Jin-Bor Chen 2. 1.
BioMed Research International Volume 2016, Article ID 1523124, 7 pages http://dx.doi.org/10.1155/2016/1523124 Research Article Association between the Achievement of Target Range CKD-MBD Markers and Mortality
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationMonth/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNew Medicines Profile. December 2013 Issue No. 13/04. Colestilan
New Medicines Profile December 2013 Issue. 13/04 Concise evaluated information to support the managed entry of new medicines in the NHS Summary (BindRen ) is an oral, non-absorbed, non-calcium, nonmetallic
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationCKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism
CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism Pieter Evenepoel Nephrology, Dialysis, and Transplantation University Hospitals Leuven April 2017, FMC Herbeumont Disclosures Research support:
More informationChronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
This is an official Northern Trust policy and should not be edited in any way Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Reference Number: NHSCT/12/553 Target
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationTotal Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism
The Journal of International Medical Research 2011; 39: 978 987 Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism J NARANDA 1,2, R EKART
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationChapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.
http://www.kidney-international.org & 2009 KDIGO Chapter 5: Evaluation and treatment of kidney transplant bone disease ; doi:10.1038/ki.2009.193 Grade for strength of recommendation a Strength Wording
More informationLa relation dialyse et nutrition
Nutrition en dialyse : controverses La relation dialyse et nutrition Charles Chazot, MD NephroCare Tassin-Charcot Sainte Foy Les Lyon, France HEMO study lessons (1) Dose Body weight flux Rocco, Kidney
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationClinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet:
Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: Results of a prospective randomized controlled study Forni Valentina¹, Pruijm Menno¹,
More informationRisk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism
Ho et al. BMC Nephrology (2017) 18:12 DOI 10.1186/s12882-016-0421-5 RESEARCH ARTICLE Open Access Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients
More informationPrevalence of malnutrition in dialysis
ESPEN Congress Cannes 2003 Organised by the Israel Society for Clinical Nutrition Education and Clinical Practice Programme Session: Nutrition and the Kidney Malnutrition and Haemodialysis Doctor Noël
More informationChapter 3.1: Diagnosis of CKD MBD: biochemical abnormalities Kidney International (2009) 76 (Suppl 113), S22 S49. doi: /ki.2009.
chapter 3.1 http://www.kidney-international.org & 2009 KDIGO Chapter 3.1: Diagnosis of CKD MBD: biochemical abnormalities. doi:10.1038/ki.2009.191 Grade for strength of recommendation a Strength Wording
More informationDrugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia
NSW Therapeutic Advisory Group Level 5, 376 Victoria Street PO Box 766 Darlinghurst NSW 2010 Phone: 61 2 8382 2852 Fax: 61 2 8382 3529 Email: nswtag@stvincents.com.au www.nswtag.org.au Drugs for the treatment
More informationLevel 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor
chapter 4.1 http://www.kidney-international.org & 2009 KDIGO Chapter 4.1: Treatment of CKD MBD targeted at lowering high serum phosphorus and maintaining serum calcium ; doi:10.1038/ki.2009.192 Grade for
More informationVelphoro (sucroferric oxyhydroxide)
STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney
More informationBONE AND MINERAL METABOLISM in the PD PATIENT
BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,
More informationAchievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study
Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study Fernstrom, Anders; Giaever, Jan; Granroth, Barbara; Hylander,
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationNDT Advance Access published February 3, 2007
NDT Advance Access published February 3, 2007 Nephrol Dial Transplant (2007) 1 of 6 doi:10.1093/ndt/gfl840 Original Article Implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationClinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2 5 and on dialysis
Nephrol Dial Transplant (2017) 32: 1114 1127 doi: 10.1093/ndt/gfx080 Advance Access publication 1 June 2017 Clinical practice recommendations for treatment with active vitamin D analogues in children with
More informationAttivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi
Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi Mario Cozzolino, MD, PhD, FERA Dipartimento di Scienze della Salute Università di Milano UO Nefrologia e Dialisi Laboratorio
More informationTO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT?
TO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT? Rana G. Rizk, PhD, MPH, LD Maastricht University, The Netherlands November, 2017 Learning objectives Review the evidence behind benefits and concerns
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationNottingham Renal and Transplant Unit
Nottingham Renal and Transplant Unit Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out
More informationKey words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis
Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet
More informationClinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages 2 5 and on dialysis
Nephrol Dial Transplant (2017) 1 14 doi: 10.1093/ndt/gfx080 Special Report Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages
More informationKDOQI COMMENTARY VOL 55, NO 5, MAY 2010
VOL 55, NO 5, MAY 2010 KDOQI COMMENTARY KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD Mineral and Bone Disorder (CKD-MBD) Katrin
More informationWhat Are the Targets in CKD-MBD?
Knowledge Exchange 2016 Paris, France, September 30, 2016 Date of preparation: Nov 2016 Item job code: INTSP/C-ANPROM/FOS/16/0025 Cristina Ortiz Jorge B Cannata-Andía Bone and Mineral Research Unit Hospital
More informationMetabolic Bone Disease (Past, Present and Future Challenges in the Management)
Metabolic Bone Disease 871 151 Metabolic Bone Disease (Past, Present and Future Challenges in the Management) SNA RIZVI INTRODUCTION The past 40 years have seen some important historical events leading
More informationOpinion 23 April 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 April 2014 MIMPARA 30 mg, film-coated tablet B/14 (CIP: 365 154 8) B/28 (CIP: 365 155 4) B/30 (CIP: 365 157 7)
More informationTABLE OF CONTENTS T-1. A-1 Acronyms and Abbreviations. S-1 Stages of Chronic Kidney Disease (CKD)
A-1 Acronyms and Abbreviations TABLE OF CONTENTS S-1 Stages of Chronic Kidney Disease (CKD) Chapter 1: Nutrition Assessment Charts, Tables and Formulas 1-2 Practical Steps to Nutrition Assessment Adult
More informationEnd stage renal disease and Protein Energy wasting
End stage renal disease and Protein Energy wasting Dr Goh Heong Keong MBBS,MRCP(UK) www.passpaces.com/kidney.htm Introduction Chronic kidney disease- increasing health burden in many countries. The estimated
More informationCalcium Management for Patients Receiving Extended Duration Hemodialysis
Calcium Management for Patients Receiving Extended Duration Hemodialysis Created November 2017; Updated March 2018 Approved by the BCPRA Home Hemodialysis Committee Table of Contents 1.0 Practice Standard...1
More informationMalnutrition and Role of Nutrition in BMD:CKD
Malnutrition and Role of Nutrition in BMD:CKD PNDS Continuing Nutrition Education Seminar Saturday, 30 th November 2013 Fayza Khan MSC (Foods and Nutrition) R.D President,PNDS Outline Objective Malnutrition
More informationManagement of mineral and bone disorders in renal transplant recipients
Nephrology 22, Suppl. 2 (2017) 65 69 Management of mineral and bone disorders in renal transplant recipients MATTHEW J DAMASIEWICZ 1,3 and PETER R EBELING 2,3,4 Departments of 1 Nephrology, and 2 Endocrinology,
More informationNicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD
Biomarker der kardio-renalen Achse Mannheim, 20. Januar 2017 Nicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD Prof. Dr. med. Thomas Bernd Dschietzig Immundiagnostik AG, Bensheim Med. Klinik m.
More informationPediatric Nutrition and Kidney Disease
Pediatric Nutrition and Kidney Disease Loai Eid, MD, MSHS, FAAP Consultant Pediatric Nephrologist Pediatric Nephrology & Hypertension Division Chief Dubai Hospital - DHA 26 th October, 2017 Objectives
More informationEffects of Lowering Dialysate Calcium Concentration on Mineral Metabolism and Hemodynamic Parameters in Hemodialysis Patients
DIALYSIS Effects of Lowering Dialysate Calcium Concentration on Mineral Metabolism and Hemodynamic Parameters in Hemodialysis Patients Ahmed Alayoud, 1 Driss El Kabbaj, 2 Mohammed Benyahia, 2 Mohammed
More informationISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world
ISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world Nutrition in Kidney Disease: How to Apply Guidelines to Clinical Practice? T. Alp
More informationOriginal Article. Introduction
Nephrol Dial Transplant (2006) 21: 1663 1668 doi:10.1093/ndt/gfl006 Advance Access publication 6 February 2006 Original Article Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism
More informationChronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist
More informationClinical Policy: Cinacalcet (Sensipar) Reference Number: CP.PHAR.61 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Sensipar) Reference Number: CP.PHAR.61 Effective Date: 05.01.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCG1339. Version: Renal Services Group. Approving forum (QIPS or equivalent):
University Hospitals Coventry & Warwickshire NHS Trust Clinical Guideline (full) CHRONIC KIDNEY DISEASE (CKD) NUTRITIONAL RECOMMENDATIONS FOR PERITONEAL DIALYSIS E-Library Reference CG1339 Version: Approving
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationYing-Ping Sun, Wen-Jun Yang, Su-Hua Li, Yuan-yuan Han, and Jian Liu
Hindawi BioMed Research International Volume 2017, Article ID 2516934, 5 pages https://doi.org/10.1155/2017/2516934 Research Article Clinical Epidemiology of Mineral Bone Disorder Markers in Prevalent
More informationPediatric CKD-MBD: pathophysiology and management
Pediatric CKD-MBD: pathophysiology and management Justine Bacchetta, MD, PhD Reference Center for Rare Renal Diseases Reference Center for Rare Diseases of Calcium and Phosphate Bron, France Overview of
More informationActual Problems in Chronic Kidney Disease - Mineral and Bone Disorder (CKD MBD) O. Mehls
Actual Problems in Chronic Kidney Disease - Mineral and Bone Disorder (CKD MBD) O. Mehls Division of Pediatric Nephrology University Hospital for Children and Adolescents Heidelberg, Germany Definition
More informationCost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients
original article http://www.kidney-international.org & 2007 International Society of Nephrology Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis
More informationUse of magnesium as a drug in chronic kidney disease
Clin Kidney J (2012) 5[Suppl 1]: i62 i70 doi: 10.1093/ndtplus/sfr168 Use of magnesium as a drug in chronic kidney disease Alastair J. Hutchison 1 and Martin Wilkie 2 1 University of Manchester and Manchester
More informationHemodialysis: slightly beyond basics Dialysate calcium and magnesium concentrations
Dialysate calcium and magnesium concentrations Stefan Farese Department of Nephrology Bürgerspital Solothurn 04.12.2013 Dialysate calcium and magnesium concentrations Do we know the optimal concentrations?
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationInternational Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.7, No.4, pp ,
International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.7, No.4, pp 560-565, 2014-2015 Comparison of Calcium, Phosphate and Intact Parathyroid Hormone Levels Pre- and Post-Parathyroidectomy
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More information